Theraclion SA announced the appointment of Yann Duchesne as Chairman of the Board of Directors after the tragic death of Christopher Bödtker mid-December. Yann Duchesne is a seasoned French executive & CEO who served on numerous boards globally. He will lead Theraclion to the next level of development and value creation.

Ex-Mckinsey Managing Partner for France, Yann Duchesne was then a Senior Partner in a leading Private Equity in London, before becoming the CEO of a major industrial and commercial conglomerate. During the past 20 years, he been on many Boards of listed or private equity owned companies, frequently as Chairman. In the healthcare space, Yann served many significant pharma companies while at McKinsey and now is the chairman of a pharmaceutical group (Medis) and is a founding shareholder in a California based biotech (Phylex).

Yann Duchesne's vision is to grow Theraclion in 3 major therapeutical areas in 3 geographies: Varicose veins, in the USA (seeking FDA clearance) and in Europe; Thyroid, in Europe and in China; Breast cancer, mostly in the USA. In order to achieve these ambitious goals, Theraclion will secure financing and strategic partnerships and will focus mostly on critical technical and clinical milestones, talent motivation and retention. Yann Duchesne's ambition is to bring Theraclion amongst the world leaders treatment device with robotics & artificial intelligence.